Fluicell AB (publ) (FLUI.ST)
SEK 11.64
(-2.18%)
SEK 11.64
(-2.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.91 Million SEK | 7.15% |
| 2022 | 8.32 Million SEK | 5.72% |
| 2021 | 7.87 Million SEK | 47.6% |
| 2020 | 5.33 Million SEK | -45.1% |
| 2019 | 9.71 Million SEK | 273.54% |
| 2018 | 2.6 Million SEK | 33.13% |
| 2017 | 1.95 Million SEK | 109.1% |
| 2016 | 934 Thousand SEK | -7.71% |
| 2015 | 1.01 Million SEK | 108.76% |
| 2014 | 484.75 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 6.23 Million SEK | -30.06% |
| 2024 Q2 | 6.32 Million SEK | 1.46% |
| 2023 FY | 8.91 Million SEK | 7.15% |
| 2023 Q1 | 5.21 Million SEK | -37.33% |
| 2023 Q2 | 6.94 Million SEK | 33.2% |
| 2023 Q4 | 8.91 Million SEK | 65.55% |
| 2023 Q3 | 5.38 Million SEK | -22.46% |
| 2022 Q2 | 8.56 Million SEK | 19.97% |
| 2022 Q4 | 8.32 Million SEK | 24.2% |
| 2022 Q1 | 7.13 Million SEK | -9.34% |
| 2022 FY | 8.32 Million SEK | 5.72% |
| 2022 Q3 | 6.69 Million SEK | -21.74% |
| 2021 Q1 | 9.23 Million SEK | 73.27% |
| 2021 FY | 7.87 Million SEK | 47.6% |
| 2021 Q4 | 7.87 Million SEK | -16.34% |
| 2021 Q3 | 9.4 Million SEK | 6.99% |
| 2021 Q2 | 8.79 Million SEK | -4.84% |
| 2020 Q4 | 5.33 Million SEK | 16.62% |
| 2020 Q1 | 8.55 Million SEK | -11.87% |
| 2020 Q2 | 13.5 Million SEK | 57.78% |
| 2020 Q3 | 4.57 Million SEK | -66.14% |
| 2020 FY | 5.33 Million SEK | -45.1% |
| 2019 Q1 | 2.89 Million SEK | 11.5% |
| 2019 FY | 9.71 Million SEK | 273.54% |
| 2019 Q4 | 9.71 Million SEK | 244.64% |
| 2019 Q3 | 2.81 Million SEK | 2.7% |
| 2019 Q2 | 2.74 Million SEK | -5.35% |
| 2018 Q3 | 2.07 Million SEK | 8.71% |
| 2018 FY | 2.6 Million SEK | 33.13% |
| 2018 Q2 | 1.9 Million SEK | -58.26% |
| 2018 Q1 | 4.56 Million SEK | 133.69% |
| 2018 Q4 | 2.6 Million SEK | 25.54% |
| 2017 Q1 | - SEK | -100.0% |
| 2017 Q4 | 1.95 Million SEK | 0.0% |
| 2017 FY | 1.95 Million SEK | 109.1% |
| 2016 FY | 934 Thousand SEK | -7.71% |
| 2016 Q4 | 934.65 Thousand SEK | 0.0% |
| 2015 FY | 1.01 Million SEK | 108.76% |
| 2014 FY | 484.75 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| 2cureX AB (publ) | 2.93 Million SEK | -203.748% |
| Abliva AB (publ) | 16.78 Million SEK | 46.874% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 30.046% |
| AcouSort AB (publ) | 10.37 Million SEK | 14.097% |
| Active Biotech AB (publ) | 13.4 Million SEK | 33.47% |
| Alzinova AB (publ) | 9.33 Million SEK | 4.458% |
| Amniotics AB (publ) | 10.54 Million SEK | 15.474% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -12.152% |
| Aptahem AB (publ) | 8.99 Million SEK | 0.921% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -101.423% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 91.637% |
| BioInvent International AB (publ) | 90.45 Million SEK | 90.144% |
| BioArctic AB (publ) | 139.5 Million SEK | 93.609% |
| Biosergen AB | 5.08 Million SEK | -75.32% |
| Biovica International AB (publ) | 34.76 Million SEK | 74.358% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 44.686% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.431% |
| Camurus AB (publ) | 414.81 Million SEK | 97.851% |
| Cantargia AB (publ) | 54.97 Million SEK | 83.782% |
| Corline Biomedical AB | 6.78 Million SEK | -31.315% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -132.282% |
| CombiGene AB (publ) | 4.15 Million SEK | -114.509% |
| Cyxone AB (publ) | 4.69 Million SEK | -89.923% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -22.796% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 87.464% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 95.846% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 35.265% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 33.111% |
| Genovis AB (publ.) | 98.04 Million SEK | 90.907% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 51.795% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.248% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 80.695% |
| Mendus AB (publ) | 51.22 Million SEK | 82.596% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 85.47% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 53.48% |
| I-Tech AB | 16.2 Million SEK | 44.986% |
| Intervacc AB (publ) | 21.68 Million SEK | 58.879% |
| Kancera AB (publ) | 17.97 Million SEK | 50.412% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 22.941% |
| LIDDS AB (publ) | 3.75 Million SEK | -137.354% |
| Lipum AB (publ) | 7.53 Million SEK | -18.267% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -72.838% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 92.809% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -277.914% |
| Nanologica AB (publ) | 79.32 Million SEK | 88.762% |
| NextCell Pharma AB | 13.68 Million SEK | 34.875% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 95.091% |
| OncoZenge AB (publ) | 1.69 Million SEK | -424.72% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -396.934% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 66.62% |
| Saniona AB (publ) | 86.08 Million SEK | 89.644% |
| Simris Alg AB (publ) | 148.93 Million SEK | 94.014% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 23.594% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 74.236% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -71.609% |
| SynAct Pharma AB | 51.83 Million SEK | 82.801% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 78.181% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 98.151% |
| Xintela AB (publ) | 14.01 Million SEK | 36.39% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 87.592% |
| Ziccum AB (publ) | 6.38 Million SEK | -39.559% |